Achaogen Inc. (AKAO) announced Monday morning that its Phase 3 trial of plazomicin met the FDA objective of non-inferiority compared to meropenem and achieved superiority for the European Medicines Agency (EMA) primary efficacy endpoints, in patients with complicated urinary tract infections and acute pyelonephritis.
from RTT - Hot Stocks http://ift.tt/2gstYcm
via IFTTT
No comments:
Post a Comment